References of "European Neuropsychopharmacology"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe involvement of GABAB receptors in antipsychotic-like effects of positive allosteric modulator of muscarinic acetylcholine M4 receptors
Cieslik, Paulina; Wozniak, Monika ULiege; Pilc, Andrzej et al

in European Neuropsychopharmacology (2017)

Detailed reference viewed: 26 (1 ULiège)
Full Text
Peer Reviewed
See detailConcomitant manipulation of NMDA- and AMPA-receptors to produce pro-cognitive drug effects
Vignisse, Julie ULiege; Steinbusch, Harry W.M.; Grigoriev, Vladimir et al

in European Neuropsychopharmacology (2014), 24

Bifunctional drug therapy targeting distinct receptor signaling systems can generate increased efficacy at lower concentrations compared to monofunctional therapy. Non-competitive blockade of the NMDA ... [more ▼]

Bifunctional drug therapy targeting distinct receptor signaling systems can generate increased efficacy at lower concentrations compared to monofunctional therapy. Non-competitive blockade of the NMDA receptors or the potentiation of AMPA receptors is well documented to result in memory enhancement. Here, we compared the efficacy of the low-affinity NMDA receptor blocker memantine or the positive modulator of AMPA receptor QXX (in C57BL/6J at 1 or 5 mg/kg, ip) with new derivatives of isothiourea (0.5-1 mg/kg, ip) that have bifunctional efficacy. Low-affinity NMDA blockade by these derivatives was achieved by introducing greater flexibility into the molecule, and AMPA receptor stimulation was produced by a sulfamide-containing derivative of isothiourea. Contextual learning was examined in a step-down avoidance task and extinction of contextual memory was studied in a fear-conditioning paradigm. Memantine enhanced contextual learning while QXX facilitated memory extinction; both drugs were effective at 5 mg/kg. The new derivative IPAC-5 elevated memory scores in both tasks at the dose 0.5 mg/Kg and exhibited the lowest IC50 values of NMDA receptor blockade and highest potency of AMPA receptor stimulation. Thus, among the new drugs tested, IPAC-5 plicated the properties of memantine and QXX in one administration with increased potency. Our data suggest that a concomitant manipulation of NMDA- and AMPA-receptors results in pro-cognitive effects and supports the concept bifunctional drug therapy as a promising strategy to replace monofunctional therapies with greater efficacy and improved compliance. [less ▲]

Detailed reference viewed: 32 (4 ULiège)
Full Text
Peer Reviewed
See detailObjective: remission of depression in primary care The Oreon Study.
Ansseau, Marc ULiege; Demyttenaere, Koen; Heyrman, Jan et al

in European Neuropsychopharmacology (2009), 19(3), 169-76

OBJECTIVE: Treatment of depression should result in the absence of symptoms, i.e. remission, in order to restore the functional status of the patient and reduce the risk for relapse. The study assessed ... [more ▼]

OBJECTIVE: Treatment of depression should result in the absence of symptoms, i.e. remission, in order to restore the functional status of the patient and reduce the risk for relapse. The study assessed the current remission rates in primary care and determined the influencing factors. METHODS: 10 consecutive depressive patients treated by antidepressants for at least 3 months and not more than 12 months were screened by each investigator. Remission rates were defined using the Hamilton-Depression scale 7 items (score of 3 or less) as well as the Carroll self rating scale (score of 7 or less). In addition, patients completed the Sheehan Disability Scale (SDS). Initial severity of depression, type of treatment and socio-economic factors were collected. RESULTS: 292 general practitioners screened a total of 2630 patients. Results indicated low remission rates: 28.3% according to the clinician and 17.1% according to the patient. Absence of remission was associated with higher impairment in work, social and family life. The most frequently reported residual symptoms in nonremitters were general somatic symptoms (92%), depressed mood (92%), psychic anxiety (91%) and impaired work and activities (89%). No differences were observed in remission rates between men and women. Remission rates were significantly lower in patients living alone as compared to those living in couple or family (25.1% vs 30.2%, p=0.03), in patients with lower education (21.3% vs 32.3%, p<0.001), in patients speaking French as compared to Dutch (24.0% vs 34.0% p<0.001), and unemployed patients compared to patients having an occupation (17.1% vs 39.0%, p<0.001). Higher initial severity and number of previous episodes decreased remission rates (p<0.001). CONCLUSION: This study shows low remission rates in depressed patients treated in general practice. The absence of remission is associated with impairment in work, social and family life. Special attention should be given to identify patients who do not reach remission. [less ▲]

Detailed reference viewed: 88 (18 ULiège)
Full Text
Peer Reviewed
See detailContingent negative variation abnormalities in posttraumatic stress disorder
Papart, Patrick ULiege; Ansseau, Marc ULiege; Bartholomé, F.

in European Neuropsychopharmacology (2008), 18(Suppl 4), 481-482

Detailed reference viewed: 30 (8 ULiège)
Full Text
Peer Reviewed
See detailEffects of attention and emotion on face processing in depression: a functional MRI study
Desseilles, Martin; Schwartz, S.; Dang-Vu, Thien Thanh et al

in European Neuropsychopharmacology (2006), 16(Suppl. 4), 271

Detailed reference viewed: 30 (2 ULiège)
Full Text
Peer Reviewed
See detailClinical characteristics of depressive episodes in Bipolar I and Bipolar II disorders
Linotte, S.; Barreto, M.; Van Geit, N. et al

in European Neuropsychopharmacology (2006), 16(Suppl. 4), 301

Detailed reference viewed: 28 (3 ULiège)
Full Text
Peer Reviewed
See detailCognitive topography imbalance in alcoholism and psychiatric comorbidity
Papart, Patrick ULiege; Liota, F.; Bartholome, F. et al

in European Neuropsychopharmacology (2006), 16(Suppl. 4), 496

Detailed reference viewed: 26 (3 ULiège)
Full Text
Peer Reviewed
See detailDepression and socio-economic status: an 8-year longitudinal population-based study
Lorant, V.; Croux, C.; Weich, S. et al

in European Neuropsychopharmacology (2006), 16(Suppl. 4), 294-295

Detailed reference viewed: 27 (1 ULiège)
Full Text
Peer Reviewed
See detailMeta-analyses of opiate maintenance therapies
Ansseau, Marc ULiege; Reggers, Jean ULiege; Somers, L. et al

in European Neuropsychopharmacology (2006), 16(Suppl. 4), 503

Detailed reference viewed: 19 (1 ULiège)
Full Text
Peer Reviewed
See detailScreening for metabolic abnormalities in patients with schizophrenia treated with antipsychotics: are we doing enough?
Van Winkel, R.; De Hert, M.; Van Eyck, D. et al

in European Neuropsychopharmacology (2006, September), 16(Suppl. 4), 398

Detailed reference viewed: 23 (4 ULiège)
Full Text
Peer Reviewed
See detailEvaluation of the metabolic safety of aripiprazole
De Hert, M.; Van Eyck, D.; Hanssens, L. et al

in European Neuropsychopharmacology (2006, September), 16(Suppl. 4), 399

Detailed reference viewed: 23 (4 ULiège)
Full Text
Peer Reviewed
See detailA cross-sectional study of adiponectin in patients with schizophrenia
Hanssens, L.; De Hert, M.; Van Eyck, D. et al

in European Neuropsychopharmacology (2006, September), 16(Suppl. 4), 430-431

Detailed reference viewed: 32 (5 ULiège)
Full Text
Peer Reviewed
See detailOXYTOCIN, VASOPRESSIN AND ANXIETY IN MAJOR DEPRESSION: AGO-ANTAGONIST NEUROHROMONES
Scantamburlo, Gabrielle ULiege; Hansenne, Michel ULiege; Fuchs, Sonia ULiege et al

in European Neuropsychopharmacology (2006), 16

Detailed reference viewed: 55 (4 ULiège)
Full Text
Peer Reviewed
See detailRapid diabetes onset and its reversal among patients treated with second generation antipsychotics
De Hert, M.; Van Eyck, D.; Hanssens, L. et al

in European Neuropsychopharmacology (2005, October), 15(Suppl. 3), 483-484

Detailed reference viewed: 40 (6 ULiège)
Full Text
Peer Reviewed
See detailSix-month incidence of diabetes among schizophrenic patients in Belgium
Hanssens, L.; De Hert, M.; Van Eyck, D. et al

in European Neuropsychopharmacology (2005, October), 15(Suppl. 3), 483

Detailed reference viewed: 25 (6 ULiège)
Full Text
Peer Reviewed
See detailPlasma oxytocin and anxiety in depressed patients
Scantamburlo, Gabrielle ULiege; Fuchs, Sonia; Pitchot, William ULiege et al

in European Neuropsychopharmacology (2005, October), 15(Suppl. 3), 430

Detailed reference viewed: 35 (3 ULiège)
Full Text
Peer Reviewed
See detailNeurophysins response to apomorphine and clonidine in major depression
Scantamburlo, Gabrielle ULiege; Ansseau, Marc ULiege; Legros, Jean-Jacques ULiege

in European Neuropsychopharmacology (2005, March), 15(Suppl. 1), 77-78

Detailed reference viewed: 18 (4 ULiège)
Full Text
Peer Reviewed
See detailDissociation between the locomotor and anxiolytic effects of acetaldehyde in the elevated plus-maze : evidence that acetaldehyde is not involved in the anxiolytic effects of ethanol in mice
Tambour, Sophie ULiege; Didone, Vincent ULiege; Tirelli, Ezio ULiege et al

in European Neuropsychopharmacology (2005), 15(6), 655-662

Acetaldehyde, the first product of ethanol metabolism, has been suggested to play a major role in many behavioral effects of ethanol. However, very few studies have directly tested the behavioral effects ... [more ▼]

Acetaldehyde, the first product of ethanol metabolism, has been suggested to play a major role in many behavioral effects of ethanol. However, very few studies have directly tested the behavioral effects of the acute administration of acetaldehyde. In particular, the role of this metabolite in ethanol-induced anxiolytic effects has never been extensively tested. The aim of the present study was to characterize the anxiolytic effects of acetaldehyde in two strains of mice, C57BL/6J and CD1 mice with the elevated plus-maze procedure. The results show that acute injections of ethanol (1-2 g/kg) induced significant dose-dependent anxiolytic effects in both strains of mice. In contrast, acetaldehyde failed to produce any anxiolytic effect, although it induced a significant hypolocomotor effect at the highest doses. In an independent experiment, cyanamide, an aldehyde dehydrogenase inhibitor, prevented the locomotor stimulant effects of ethanol, although it failed to alter its anxiolytic effects. Together, the results of the present study indicate that acetaidehyde is not involved in ethanol-induced anxiolytic effects, although it may be involved in its sedative/hypolocomotor effects. (c) 2005 Elsevier BX and ECNP. All fights reserved. [less ▲]

Detailed reference viewed: 60 (13 ULiège)
Full Text
Peer Reviewed
See detailAdaptation and validation of the ASAM PPC-2R criteria in French and Dutch speaking Belgian drug-addicts
Reggers, Jean ULiege; Ansseau, Marc ULiege; Gustin, F. et al

in European Neuropsychopharmacology (2004), 14(Suppl. 3), 354-355

Detailed reference viewed: 16 (1 ULiège)
Full Text
Peer Reviewed
See detailThe use of the PHQ as follow-up instrument for MDD in the primary care setting
Demyttenaere, K.; Pitchot, William ULiege; Albert, Adelin ULiege et al

in European Neuropsychopharmacology (2004, October), 14(Suppl. 3), 214

Detailed reference viewed: 22 (1 ULiège)